

Issued: 15 October 2025

Viral Vector Manufacturing Facility (VVMF) and Chimeric Therapeutics sign Letter of Intent to provide GMP manufacturing of viral vectors in Australia for global clinical applications

JOINT RELEASE with Chimeric Therapeutics

Sydney, Australia, 15 October 2025

Viral Vector Manufacturing Facility Pty Ltd (VVMF) and Chimeric Therapeutics (ASX:CHM, "Chimeric") have co-signed a **Letter of Intent (LOI)** to enter a strategic supplier relationship focused on the **development and GMP-grade manufacturing of Lentiviral vectors (LV)**.

Under the LOI, VVMF will support process development, technology transfer, and GMP manufacturing of Lentiviral vectors for Chimeric's clinical stage chimeric antigen receptor (CAR-T) program. Viral vectors are a critical component in the production of CAR-T therapies, which are transforming cancer treatment globally.

This partnership marks a significant step forward in strengthening **Australia's advanced manufacturing capabilities and the development of Advanced Therapy Medicinal Products (ATMPs)**. ATMPs are innovative medicines derived from genes, cells, or tissue engineering. They often involve living cells or tissues, requiring highly specialised manufacturing and handling. These therapies offer new treatment possibilities for a range of diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions.

Australia is recognised globally for its support of early-stage biotech companies with significant R&D tax incentives for eligible activities, a globally recognised and pragmatic regulatory environment, and access to a mature clinical trial ecosystem. This collaboration will enhance access to cutting-edge therapies for both Australian and international patients with expanded local clinical trial sites.



Stephen Thompson, VVMF CEO, said: "We are excited to be supporting Chimeric's clinical development program as Australia's first and only commercial-scale viral vector manufacturer. This collaboration strengthens sovereign advanced manufacturing, supports the creation of high-value jobs in Western Sydney, and allows us to demonstrate our capability to develop and manufacture GMP-grade viral vectors for the global cell and gene therapy marketplace."



Dr Rebecca McQualter, Chimeric Therapeutics CEO, said: "We're pleased to partner with VVMF as we continue to advance our CAR-T cell therapy programs. Having access to local, GMP-grade viral vector manufacturing not only strengthens our supply chain but also supports the broader goal of building world-class advanced therapy capabilities here in Australia."

About VVMF – Unlocking the Future of Medicine

Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) is Australia's only Contract Development and Manufacturing Organisation (CDMO) dedicated to providing services in the research, design, development, and manufacture of viral vectors for advanced therapeutic applications. VVMF partners with researchers, clinicians, and bio-pharma companies to accelerate the path to market for cell and gene therapies to local and global patients.

Viral vectors play a crucial role in delivering genetic material into cells and are central to innovative treatments in areas of medicine including cancers and rare diseases.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

For further information please contact

VVMF

media@vvmf.com.au

Chimeric Media

Matthew Wright NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au